Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone

E. Riva, P. L. Farina, R. Sega, G. Tognoni, W. Bastain, J. McAinsh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The pharmacokinetics of atenolol with and without the co-administration of chlorthalidone were studied in five hypertensive subjects. Concomitant administration of chlorthalidone appears to have little if any effect on the pharmacokinetics of atenolol during treatment for 7 days. The atenolol elimination half-lives were 6.7±1.1 and 6.3±0.9 h, respectively, with and without chlorthalidone. Two healthy volunteers also received a single 50 mg oral dose of chlorthalidone. Their blood profiles and pharmacokinetics were similar to those observed in hypertensive subjects, but a statistically significant difference (p

Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Volume17
Issue number5
DOIs
Publication statusPublished - Sep 1980

Fingerprint

Chlorthalidone
Atenolol
Pharmacokinetics
Healthy Volunteers

Keywords

  • atenolol
  • chlorthalidone
  • chronic treatment
  • co-administration
  • hypertension
  • plasma half-life
  • urine half-life

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone. / Riva, E.; Farina, P. L.; Sega, R.; Tognoni, G.; Bastain, W.; McAinsh, J.

In: European Journal of Clinical Pharmacology, Vol. 17, No. 5, 09.1980, p. 333-337.

Research output: Contribution to journalArticle

Riva, E. ; Farina, P. L. ; Sega, R. ; Tognoni, G. ; Bastain, W. ; McAinsh, J. / Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone. In: European Journal of Clinical Pharmacology. 1980 ; Vol. 17, No. 5. pp. 333-337.
@article{65b14447924440c09dbcfab393597516,
title = "Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone",
abstract = "The pharmacokinetics of atenolol with and without the co-administration of chlorthalidone were studied in five hypertensive subjects. Concomitant administration of chlorthalidone appears to have little if any effect on the pharmacokinetics of atenolol during treatment for 7 days. The atenolol elimination half-lives were 6.7±1.1 and 6.3±0.9 h, respectively, with and without chlorthalidone. Two healthy volunteers also received a single 50 mg oral dose of chlorthalidone. Their blood profiles and pharmacokinetics were similar to those observed in hypertensive subjects, but a statistically significant difference (p",
keywords = "atenolol, chlorthalidone, chronic treatment, co-administration, hypertension, plasma half-life, urine half-life",
author = "E. Riva and Farina, {P. L.} and R. Sega and G. Tognoni and W. Bastain and J. McAinsh",
year = "1980",
month = "9",
doi = "10.1007/BF00558445",
language = "English",
volume = "17",
pages = "333--337",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone

AU - Riva, E.

AU - Farina, P. L.

AU - Sega, R.

AU - Tognoni, G.

AU - Bastain, W.

AU - McAinsh, J.

PY - 1980/9

Y1 - 1980/9

N2 - The pharmacokinetics of atenolol with and without the co-administration of chlorthalidone were studied in five hypertensive subjects. Concomitant administration of chlorthalidone appears to have little if any effect on the pharmacokinetics of atenolol during treatment for 7 days. The atenolol elimination half-lives were 6.7±1.1 and 6.3±0.9 h, respectively, with and without chlorthalidone. Two healthy volunteers also received a single 50 mg oral dose of chlorthalidone. Their blood profiles and pharmacokinetics were similar to those observed in hypertensive subjects, but a statistically significant difference (p

AB - The pharmacokinetics of atenolol with and without the co-administration of chlorthalidone were studied in five hypertensive subjects. Concomitant administration of chlorthalidone appears to have little if any effect on the pharmacokinetics of atenolol during treatment for 7 days. The atenolol elimination half-lives were 6.7±1.1 and 6.3±0.9 h, respectively, with and without chlorthalidone. Two healthy volunteers also received a single 50 mg oral dose of chlorthalidone. Their blood profiles and pharmacokinetics were similar to those observed in hypertensive subjects, but a statistically significant difference (p

KW - atenolol

KW - chlorthalidone

KW - chronic treatment

KW - co-administration

KW - hypertension

KW - plasma half-life

KW - urine half-life

UR - http://www.scopus.com/inward/record.url?scp=0018818984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018818984&partnerID=8YFLogxK

U2 - 10.1007/BF00558445

DO - 10.1007/BF00558445

M3 - Article

C2 - 7418712

AN - SCOPUS:0018818984

VL - 17

SP - 333

EP - 337

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -